Search clinical trials for: 7.5μg H7N9 Vaccine

Total 6214 results

National Institute of Allergy and Infectious Diseases...

Completed

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

Influenza

United States
Shanghai Institute Of Biological Products
Henan Center for Disease Control and Prevention

Unknown

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

H7N9 Influenza

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Withdrawn

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Influenza
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Influenza A Virus, H7N9 Subtype

United States
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Influenza A Virus, H7N9 Subtype

United States
Research Institute of Influenza, Russia
World Health Organization; Institute of Experimental Medicine, Russia

Completed

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

Influenza
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Influenza A Virus, H7N9 Subtype

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Avian Influenza | Immunisation

United States
Hualan Biological Bacterin Co. Ltd.

Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Influenza A
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Boost in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

2013/2017 H7N9 Prime-Boost Interval

Influenza Immunisation | Avian Influenza

United States
Butantan Institute

Completed

Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

Influenza | H7N9 Influenza

Brazil
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Influenza | Avian Influenza | H1N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH)

Completed

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

Influenza A

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Influenza A Subtype H7N7 Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older

Influenza

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Avian Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
Research Institute of Influenza, Russia
World Health Organization; Institute of Experimental Medicine, Russia; Joint...

Unknown

Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine

Vaccine Adverse Reaction
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Prostate Cancer

United States
Novavax

Completed

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Avian Influenza

Australia
Genocea Biosciences, Inc.

Completed

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

Genital Herpes Simplex Type 2

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission

Breast Cancer
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
Medical University of South Carolina

Completed

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Aging | HIV Lipodystrophy

United States
Genocea Biosciences, Inc.

Completed

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

Genital Herpes Simplex Type 2

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Novavax
Department of Health and Human Services

Completed

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Influenza (Pandemic)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

Cytomegalovirus Infection | Healthy, no Evidence of Disease

United States
Shanghai Institute Of Biological Products

Unknown

A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine

H7N9 Influenza

China
BTG International Inc.
Encorium

Terminated

Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension

Hypertension | Cardiovascular Disease

United Kingdom

Search clinical trials for: 7.5μg H7N9 Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations